Testing vicadrostat with empagliflozin for heart failure with weak pump
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with heart failure for at least 3 months and your heart's pumping function is below 40%.
- You have shortness of breath or fatigue that limits your daily activities (NYHA class II to IV).
- You are not currently taking certain medications like spironolactone, eplerenone, or amiloride.
- You have not had a heart attack, stroke, or major heart surgery in the last 90 days.
- You do not have a heart transplant, are not waiting for one, and do not have a mechanical heart pump device.
- You are willing to use highly effective birth control if you are a woman of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
This study compares three different combinations of medicines to see which one works best for people with heart failure and a preserved ejection fraction (a type of heart failure where the heart's pumping function is normal but it doesn't fill properly). Participants will receive one of three treatments: vicadrostat plus empagliflozin, empagliflozin alone, or empagliflozin plus spironolactone. The study looks at how these medicines affect proteins in the blood, which may help doctors understand which treatment is more effective.
This study compares how two different tablet versions of a combination of vicadrostat and empagliflozin are absorbed by the body. It is for healthy volunteers to see which form works better.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.